Latest Aragon Pharmaceuticals Inc. Stories

2010-08-09 07:00:00

SAN DIEGO, Aug. 9 /PRNewswire/ -- Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC). The Phase 1 portion of the study, being conducted at the Memorial Sloan-Kettering Cancer Center in New York City, is an open-label, dose-escalating trial evaluating the safety and tolerability of ARN-509 in patients with progressive metastatic...

2010-04-22 07:00:00

SAN DIEGO, April 22 /PRNewswire/ -- Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors and The Column Group. The financing brings the total dollar amount raised to $30 million since the company's formation in May 2009. "Aragon is using a novel approach to create first-in-class and best-in-class drugs for hormonally driven cancers,"...

Word of the Day
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.